Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of TQ05105 + TQB3617 in intermediate- or high-risk myelofibrosis
CTR20232475Phase 2Active
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of rovadicitinib, TQB3617 in myelofibrosis (MF), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started Dec 2023; status: active.
02
Drugs
rovadicitinibTQB3617
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on CTR20232475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232475.